Although these reports suggest efficacy and safety of DPP-4 inhibitors for the treatment of patients with type 2 diabetes undergoing HD, caution should still be exercised when treating patients undergoing HD. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.